Hypercalcemia
📧 Sign up to get email alerts when something new happens for Hypercalcemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-01-25Clinical Trial Update: Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy [Phase 3]
Phase 3 trial assessing cinacalcet for hypercalcemia in primary hyperparathyroidism patients unable to undergo parathyroidectomy; results co…
-
FDA approval · 2015-10-31FDA Approved: CALCITONIN SALMON — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application from Apotex Corp. for calcitonin salmon (generic), resulting in an updated approval under the ANDA p…
-
FDA approval · 2015-10-31FDA Approved: CALCITONIN SALMON — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for Calcitonin Salmon submitted by Endo USA, Inc.
-
CLINICAL_TRIALS trial_result · 2015-05-22Clinical Trial Update: Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients. [Phase 2]
A Phase 2 trial evaluating calcium dialysate at 1.25 mmol/L for mineral metabolism in haemodialysis patients has completed.
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D [Phase 2, Phase 3]
A Phase 2/3 clinical trial investigating the early effect of Vitamin D in primary hyperparathyroidism has been withdrawn. The study relates …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-02-02FDA Approved: MIACALCIN — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for Miacalcin (calcitonin salmon) submitted by Mylan Institutional LLC.
-
CLINICAL_TRIALS research · 2015-01-26Clinical Trial Update: ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study [Phase 2, Phase 3]
Open-label pilot study of ACTHAR Gel for sarcoidosis-associated calcium dysregulation (hypercalcemia), spanning Phase 2 and Phase 3, with cu…
-
CLINICAL_TRIALS research · 2014-04-16Clinical Trial Update: Differentially Expressed Proteins in Sporadic Parathyroid Tumors
This clinical trial update reports on differentially expressed proteins in sporadic parathyroid tumors. The work is in the setting of primar…
-
CLINICAL_TRIALS trial_result · 2013-10-16Clinical Trial Update: Effect of Vitamin D Treatment in Primary Hyperparathyroidism [Phase 2, Phase 3]
Phase 2 and Phase 3 trial results evaluating Vitamin D therapy in primary hyperparathyroidism have been completed, with results posted in 20…
-
FDA approval · 2013-02-19FDA Approved: MIACALCIN — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for Miacalcin (calcitonin salmon) submitted by Mylan Institutional LLC. The action pertains to a…
-
FDA approval · 2012-07-12FDA Approved: CALCITONIN SALMON — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for Calcitonin Salmon from Endo USA, Inc.
-
FDA approval · 2012-04-25FDA Approved: CALCITONIN SALMON — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for Calcitonin Salmon from Apotex Corp., updating the approved product's regulatory status.
-
CLINICAL_TRIALS trial_result · 2011-11-21Clinical Trial Update: Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community [NA]
Completed clinical trial evaluating zoledronic acid (Zometa) for tumor-induced hypercalcemia and malignant bone pain. The study was sponsore…
-
CLINICAL_TRIALS trial_result · 2011-10-31Clinical Trial Update: Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose [Phase 4]
Phase 4 trial evaluating the effectiveness and safety of intravenous Zemplar (paricalcitol) in patients on hemodialysis with secondary hyper…
-
EMA withdrawal · 2011-08-22EMA Application withdrawn: Ibandronic Acid Hexal (ibandronic acid) — Hexal AG
The EMA withdrew the application for Ibandronic Acid Hexal (ibandronic acid) from the market. Therapeutic areas listed include hypercalcemia…
-
FDA approval · 2011-08-01FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)
The FDA approves a supplemental application for Sensipar (cinacalcet hydrochloride) submitted by Amgen Inc.
-
CLINICAL_TRIALS research · 2010-10-22Clinical Trial Update: The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration
A clinical-trial update describing a minimally invasive parathyroid surgical approach that requires precise identification and localization …
-
CLINICAL_TRIALS trial_result · 2010-01-05Clinical Trial Update: Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects [NA]
A completed clinical trial evaluating oral peptone loading in adults with primary hyperparathyroidism and hypercalcemia, as well as healthy …
-
EMA withdrawal · 2009-12-31EMA Withdrawn: Destara (ibandronic acid) — Roche Registration Ltd.
Destara (ibandronic acid) has been withdrawn from the European market by Roche Registration Ltd., affecting indications in hypercalcemia and…
-
FDA approval · 2009-11-12FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)
The FDA approved Amgen's supplemental application for SENSIPAR (cinacalcet hydrochloride), resulting in updated labeling for the product.
-
FDA label_change · 2009-10-30FDA Approved: MIACALCIN — Supplemental Application (Mylan Institutional LLC)
FDA's page describes a supplemental application for Miacalcin (calcitonin salmon) submitted by Mylan Institutional LLC. The document signals…
-
FDA approval · 2009-06-08FDA Approved: CALCITONIN SALMON — Original Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s Original Application for Calcitonin Salmon (generic), confirming a generic product for the drug. The approval …
-
EMA withdrawal · 2009-05-14EMA Withdrawn: Parareg (cinacalcet) — Dompé Biotec S.p.A.
EMA withdrawn status for Parareg (cinacalcet) by Dompé Biotec S.p.A., with therapeutic areas including hypercalcemia, parathyroid neoplasms,…
-
EMA withdrawal · 2008-11-20EMA Withdrawn: Forcaltonin (recombinant salmon calcitonin) — Unigene UK Ltd.
Forcaltonin (recombinant salmon calcitonin) has been withdrawn from the EMA; previously indicated for hypercalcemia, osteitis deformans, and…
-
FDA approval · 2008-11-17FDA Approved: CALCITONIN SALMON — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original ANDA for Calcitonin Salmon, authorizing a generic version of the drug for its approved uses.